Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Summary

The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Timeline

Start

2011-02

Primary completion

2011-09

Completion

2011-11

Outcome

Outcome not reported

Stopped (Enrollment): “Recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated.”

Drugs

Indications